Evidence map›Paper›PMID 41526373›Full record

ArticleNPJ Parkinson's disease2026

Delphinidin modulates neuroinflammation and behavioral deficits in a Parkinson's disease mouse model.

A Grotemeyer, S Alexander, L Frieß, J Roewer, E E Bankoglu, M Badr, J Wu, H Stopper, J Volkmann, N Roewer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

A GrotemeyerDepartment of Neurology, University Hospital of Wuerzburg, Würzburg, Germany.
S AlexanderDepartment of Neurology, University Hospital of Wuerzburg, Würzburg, Germany.
L FrießDepartment of Neurology, University Hospital of Wuerzburg, Würzburg, Germany.
J RoewerDermatologikum Hamburg, Hamburg, Germany.
E E BankogluInstitute of Pharmacology and Toxicology, University of Wuerzburg, Würzburg, Germany.
M BadrDepartment of Neurology, University Hospital of Wuerzburg, Würzburg, Germany.
J WuDepartment of Neurology, University Hospital of Wuerzburg, Würzburg, Germany.
H StopperInstitute of Pharmacology and Toxicology, University of Wuerzburg, Würzburg, Germany.
J VolkmannDepartment of Neurology, University Hospital of Wuerzburg, Würzburg, Germany.
N RoewerZentrum für Operative Medizin (Chirurgie I), University Hospital of Wuerzburg, Würzburg, Germany.
C W IpDepartment of Neurology, University Hospital of Wuerzburg, Würzburg, Germany. Ip_c@ukw.de.

Funding

Deutsche Forschungsgemeinschaft 424778381-TRR 295 A01, A06
6 · The paper itself

Abstract

Neuroinflammation is deeply intertwined with dopaminergic (DA) neurodegeneration in Parkinson's disease (PD). We tested whether delphinidin, an anthocyanidin with reported inflammasome/NF-κB modulatory activity, alters neuroinflammation and nigrostriatal integrity in a progressive AAV1/2-A53T α-synuclein (hαSYN) mouse model. Once-daily intraperitoneal delphinidin for nine weeks modestly ameliorated asymmetric forepaw use, attenuated the hαSYN-induced loss of striatal TH⁺ terminal density, and was associated with modest alterations in dopamine turnover, yet did not prevent the loss of DA neurons in the substantia nigra (SN). On the immunological level, delphinidin attenuated the innate immune response by reducing the number and activity of CD11b

Identifiers

PMID41526373
PMCPMC12855252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.